Furthering scientific discovery starts with
a passionate drive to solve the challenges
others believe are impossible.
We are taking on the challenges of complex and debilitating conditions and are committed to meeting the needs of people suffering from serious and often life-threatening illnesses. Today, MTPC group companies are focused on driving scientific discovery in many areas, including amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
Research in ALS has always been extraordinarily difficult, due in part to the significant heterogeneity of the disease. Prior to 2017, 86 clinical trials exploring more than 50 compounds were conducted, yet no Phase 3 studies in ALS demonstrated a meaningful positive effect on slowing or eliminating functional disease progression.
Clinical research of our ALS treatment diverged from typical clinical development design strategies previously used for ALS studies. It required demonstration of clinically meaningful efficacy within a limited time period of only six months after first dose, instead of endpoints measured in years. It prioritized the importance of day-to-day capabilities — the ability to climb stairs, swallow food and others, using the ALSFRS-R functional rating scale.
Innovative efforts implemented by the development program helped to advance the conversation about current and future paradigms for ALS clinical trial studies.
We know people with ALS and their families never give up and neither did we. Our determined researchers went to work on a disease that was not well understood. Each clinical trial became an opportunity to learn more about ALS and how edaravone could benefit patients.
Our focus remains on bringing treatment to people living with ALS as we strive to make a meaningful difference in their lives. We continue to expand our work to deepen our understanding of ALS, explore potential biomarkers to aid in further research and seek new answers.
MTPC group companies have invested in a private biotech company focused on discovering and developing new precision therapies to target distinct subtypes of ALS, including a device to remove toxic proteins and a drug that restores a dysfunctional waste clearance system in cells. MTPC group companies also have in place several research partnerships to investigate potential effects on ALS.
The second most common neurodegenerative disease in the elderly behind Alzheimer’s, PD affects 10 million people worldwide, yet there’s still no cure. The condition presents with significant morbidity and disability and involves both motor impairments, such as tremors, walking difficulties and postural imbalance, and non-motor impairments, such as sleeping disorders, mood disturbances, anxiety and depression. In some cases, psychotic symptoms can occur. We will not rest until strides are made to improve quality of life for people living with this neurodegenerative disease.
Always looking to the future, we have begun to explore new potential treatment options that we hope will help control the difficult symptoms and motor fluctuations associated with Parkinson’s disease. We hope the new data from our expanding CNS portfolio will provide further understanding and better treatment of this disease.
In addition to our scientific research in the space, we’re committed to educating patients on how to communicate their symptoms to HCPs. Staying abreast of the correct terminology, how the disease progresses and movement-related symptoms (motor fluctuations) can put patients on the path to better care. It’s time we all became “fluent” in Parkinson’s.
Mitsubishi Tanabe Pharma America is driving discovery every day through smart science with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases.
Our Global PipelineClinical trials are a fundamental part of clinical research and help answer key questions in health care and drug development.
MTPA contributes to a deeper understanding of complex diseases by sharing findings with the scientific community.
Read MoreFor decades, we’ve been dedicated to research that drives scientific discovery for some of the most difficult-to-treat diseases.
Learn MoreMTPA will register and disclose information on publicly accessible clinical trial registries such as ClinicalTrials.gov regarding clinical trials that are being conducted or have been conducted.
MTPA will disclose the results from clinical trials in patients that form part of the submission package for products approved in the United States. Results will not be disclosed if MTPA decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions: